United Kingdom Pharmaceutical Market Analysis, 2010-2014

Having displayed fluctuating growth rates in the years 2005-2009 the UK pharmaceuticals market is expected to stabilize over the years up to 2014.

The UK pharmaceuticals market generated total revenues of $25,681.9 million in 2009, representing a compound annual growth rate (CAGR) of 3.2% for the period spanning 2005-2009. In comparison, the French and German markets grew with CAGRs of 3.2% and 3.1% respectively, over the same period, to reach respective values of $37,306.2 million and $37,139.2 million in 2009.

Central nervous system sales proved the most lucrative for the UK pharmaceuticals market in 2009, generating total revenues of $5,945.3 million, equivalent to 23.1% of the market's overall value. In comparison, cardiovascular sales generated revenues of $4,875.9 million in 2009, equating to 19% of the market's aggregate revenues.

This report highlights the United Kingdom pharmaceutical sector in terms of market share, key trends, market players and competitive scenario in the market.

Key Highlights:
- Current market scenario of United Kingdom pharmaceutical market, by revenue, geographic regions, product types, and market players.
- Competitive analysis of the pharmaceutical sector by each country via-a-vis global market
- Market forecast of United Kingdom Pharmaceuticals market, by revenue till 2014.
- Covered more than 12 company profiles in the pharmaceutical sector covering their performance, key financials, SWOT analysis, and investment analysis.

Venn Research, in association to its network of partners provides information and research to thousands of clients worldwide. The information provided herein has been obtained from reliable sources to provide a holistic survey on the market dynamics. SHOW LESS READ MORE >

1 United Kingdom Pharmaceuticals Market, 2010
1.1 Quick Glance at the Market
1.2 Market Scenario
2 United Kingdom Pharmaceuticals Market, By Categories, 2010
3 United Kingdom Pharmaceuticals Market, By Market Players, 2010
4 United Kingdom Pharmaceuticals Market Outlook, 2011- 2014
5 United Kingdom Pharmaceuticals Market - Competitive Analysis
6 Company Profiles
6.1 Almirall Prodesfarma SA
6.1.1 Key Financials
6.1.2 Overview
6.1.3 Subsidiaries
6.1.4 Products and Services Analysis
6.1.5 Research and Development
6.2 Astellas Pharma
6.2.1 Key Financials
6.2.2 Overview
6.2.3 Subsidiaries
6.2.4 Products And Services Analysis:
6.2.5 SWOT Analysis
6.2.6 Company View
6.3 AstraZeneca PLC
6.3.1 Overview
6.3.2 Subsidiaries
6.3.3 Products and Services Analysis
6.3.4 Competitor Analysis
6.3.5 SWOT Analysis
6.4 The Menarini Group
6.4.1 Overview
6.4.2 Subsidiaries
6.4.3 Competitor Analysis
6.4.4 SWOT Analysis
6.5 EGIS Pharmaceuticals Plc
6.5.1 Overview
6.5.2 Subsidiaries
6.5.3 Products and Services Analysis
6.5.4 SWOT Analysis
6.6 Gedeon Richter Ltd
6.6.1 Overview
6.6.2 Subsidiaries
6.6.3 Competitor Analysis
6.6.4 SWOT Analysis
6.6.5 Investment Analysis
6.7 GlaxoSmithKline Plc
6.7.1 Key Financials
6.7.2 Overview
6.7.3 Subsidiaries
6.7.4 Products and Services Analysis
6.7.5 Competitor Analysis
6.7.6 SWOT Analysis
6.7.7 Investment Analysis
6.8 Les Laboratoires Servier
6.8.1 Overview
6.8.2 Competitor Analysis
6.8.3 SWOT Analysis
6.9 Novartis AG
6.9.1 Key Financials
6.9.2 Overview
6.9.3 Segments
6.9.4 Products and Services Analysis
6.9.5 Competitor Analysis
6.9.6 SWOT Analysis
6.10 Nycomed International Management GmbH
6.10.1 Key Financials
6.10.2 Overview
6.10.3 Products and Services Analysis
6.10.4 Competitor Analysis
6.10.5 SWOT Analysis
6.11 Orifarm A/S
6.11.1 Overview
6.12 Pharmstandard
6.12.1 Overview

List of Tables:
Table 1: United Kingdom Pharmaceuticals Market, ($Billions) 2005-2010
Table 2: United Kingdom Pharmaceuticals Market, By Categories, 2010
Table 3: United Kingdom Pharmaceuticals Market, By Market Players, 2010
Table 4: United Kingdom Pharmaceuticals Market Outlook, ($Billions) 2011-2014
Table 5: Almirall Prodesfarma SA - Key Financials, 2008-2009
Table 6: Almirall Prodesfarma SA Sales, By Distribution Channels
Table 7: Almirall Prodesfarma SA Sales, By Geography
Table 8: Almirall Prodesfarma SA Sales, By Therapeutic Area
Table 9: Almirall Prodesfarma SA Sales, By Brand Names
Table 10: Astellas Pharma - Key Financials, 2008-2010
Table 11: Astellas Pharma - Historical Stock Information
Table 12: Astellas Pharma Sales, By Geography
Table 13: Astellas Pharma Sales, By Products
Table 14: AstraZeneca Sales, By Products, 2009
Table 15: AstraZeneca Sales, By Geography, 2009
Table 16: The Menarini Group Sales 2009
Table 17: The Menarini Group Employees, 2009
Table 18: Gedeon Richter Plc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2010
Table 19: Gedeon Richter Plc., Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2010
Table 20: GlaxoSmithKline Plc - Key Financials
Table 21: GlaxoSmithKline Plc - Histroical Stock Information
Table 22: GlaxoSmithKline Plc Sales, By Geography, 2009
Table 23: GlaxoSmithKline Plc Sales, By Products and Services, 2009
Table 24: GlaxoSmithKline plc, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2010
Table 25: GlaxoSmithKline plc, Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2010
Table 26: GlaxoSmithKline plc, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2010
Table 27: GlaxoSmithKline plc, Pharmaceuticals & Healthcare, Deals By Sector, 2005 to YTD 2010
Table 28: Novartis AG - Key Financials
Table 29: Novartis AG - Historical Stock Information
Table 30: Novartis AG Sales, By Products and Servces, 2009
Table 31: Novartis AG Pharmaceuticals Sales, 2009
Table 32: Novartis AG Sales, By Geogrphy, 2009
Table 33: Nycomed International Management GmbH - Key Financials
Table 34: Orifarm A/S - Key Financials

List of Figures:
Figure 1: United Kingdom Pharmaceuticals Market, ($Billions) 2005-2010
Figure 2: United Kingdom Pharmaceuticals Market, By Categories, 2010
Figure 3: United Kingdom Pharmaceuticals Market, By Market Players, 2010
Figure 4: United Kingdom Pharmaceuticals Market Outlook, ($Billions) 2011-2014
Figure 5: Almirall Prodesfarma SA Sales, By Geography
Figure 6: Almirall Prodesfarma SA - Research and Development Growth, 2011-2013

Almirall Prodesfarma SA
Astellas Pharma
AstraZeneca PLC
The Menarini Group
EGIS Pharmaceuticals Plc
Gedeon Richter Ltd
GlaxoSmithKline Plc
Les Laboratoires Servier
Novartis AG
Nycomed International Management GmbH
Orifarm A/S
Pharmstandard